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In an immune response, CD4+ T cells expand into
effector T cells and then contract to survive as
long-lived memory cells. To identify age-associated
defects in memory cell formation, we profiled acti-
vated CD4+ T cells and found an increased induction
of the ATPase CD39 with age. CD39+ CD4+ T cells
resembled effector T cells with signs of metabolic
stress and high susceptibility to undergo apoptosis.
Pharmacological inhibition of ATPase activity
dampened effector cell differentiation and improved
survival, suggesting that CD39 activity influences
T cell fate. Individuals carrying a low-expressing
CD39 variant responded better to vaccination
with an increase in vaccine-specific memory
T cells. Increased inducibility of CD39 after acti-
vation may contribute to the impaired vaccine
response with age.INTRODUCTION
Aging is associated with a decline in immune function, contrib-
uting to the increased susceptibility to infectious diseases and
higher incidence of malignant disease (Goronzy and Weyand,
2013; Montecino-Rodriguez et al., 2013; Thompson et al.,
2003; Weng, 2006). As a consequence of the impaired adaptive
immune response, vaccinations are less efficacious. While naive
T cell responses are particularly compromised (Petersen et al.,
2013), memory T cell responses are also impaired as docu-
mented by the reduced efficacy of annual influenza vaccinations
or the poor recall response to varicella zoster immunization
(Dormitzer et al., 2011; Levin, 2012).
Most studies exploring mechanistic defects have focused on
the early stages of an immune response (Goronzy and Weyand,
2013; Haynes and Swain, 2012; Zhang et al., 2014). In contrast to
the mouse, age-associated changes in T cell repertoire compo-
sition are not sufficient to explain the failure in human immune
competence with age. The number of naive T cells declines
with age; however, at least for CD4+ T cells, the decline ismodest1218 Cell Reports 14, 1218–1231, February 9, 2016 ª2016 The Autho(Wertheimer et al., 2014), and the T cell receptor (TCR) repertoire
continues to be sufficiently diverse in older adults to include
T cell specificities to most if not all exogenous antigens (Qi
et al., 2014). An increased threshold to respond to TCR triggering
due to increased expression of the dual-specific phosphatase 6
is likely to compromise stimulation by low-affinity peptides for
naive cells (Li et al., 2012).
Later phases of the T cell response have been less explored
for age-associated defects. Subsequent to TCR stimulation,
antigen-specific T cells exponentially expand and differentiate
into effector cells. Most of these expanded cells undergo
apoptosis; a few of them survive as long-lived memory cells
(Kaech and Wherry, 2007; Williams and Bevan, 2007). CD8+
T cells only require a short encounter with antigen to clonally
expand and develop into effector cells (Kaech and Ahmed,
2001). The cell surface marker KLRG1 and the interleukin-7
(IL-7) receptor are useful to identify murine CD8+ effector
T cells that survive and transition into memory cells (Kaech
et al., 2003; Sarkar et al., 2008). CD4+ T cells require ongoing
antigenic stimulation during clonal expansion. Transition into
memory cells is dependent on the strength of the TCR signal,
and only high-affinity T cells survive (van Leeuwen et al.,
2009; Williams et al., 2008). The mechanisms regulating CD4+
effector cell clonal downsizing versus memory cell differentia-
tion are undetermined. Ly6C has been suggested as pheno-
typic marker of CD4+ memory cell precursors in the murine
effector cell population but does not exist in humans (Marshall
et al., 2011).
The current study was designed to identify age-associated
differences in the gene expression of human CD4+ effector
cells that correlate with their propensity to undergo apoptosis
or to survive as long-lived memory T cells. We identified the
ecto-ATP/ADPase CD39 expressed on the subset of activated
CD4+ T cells that is prone to apoptosis. Rather than a surro-
gate marker, we found the ATPase activity to be directly
involved in T effector cell differentiation and apoptosis. CD39
was more frequently induced in T cell responses of old than
young individuals. Increased expression of CD39, either due
to age or to genetic polymorphism, may render individuals
more susceptible to T cell apoptosis, resulting in the genera-
tion of a reduced number of long-lived memory T cells after
vaccination.rs
RESULTS
Age-Associated Increase in CD39 Expression after
T Cell Activation
To identify genetic programs that are distinct in CD4+ T cells of
young and old individuals, we profiled transcripts in CD4+ mem-
ory T cells that were stimulated in vitro by dendritic cells (DCs)
and the superantigen TSST-1 (GEO: GSE36476). We identified
genes that were differentially expressed at 48 and 72 hr after
stimulation and not in unstimulated T cells or early after activa-
tion (Yu et al., 2012). We hypothesized that these genes
contribute to defective adaptive immune responses in older indi-
viduals by compromising effector function and generation of
long-lived memory T cells. Ectonucleoside triphosphate diphos-
phohydrolase (ENTPD) 1, a cell membrane ATPase also referred
to as CD39, was significantly overexpressed in the gene arrays of
stimulated older CD4+ memory T cells. Variable expression in
humans has been attributed to an A-to-G SNP at position
rs_10748643 (Friedman et al., 2009). No significant age-associ-
ated differences in SNP distributions were found;30%of either
the young or older population carried the low-expressing A/A ge-
notype (Table S1). Flow cytometry confirmed that the A/A SNP
correlated with low to absent CD39 cell surface expression on
activated CD4+ T cells. In all subsequent comparisons between
young and older T cells, individuals carrying the A/A SNP geno-
type were therefore excluded.
Gene expression array findings were confirmed by qPCR us-
ing CD4+ memory T cells from 20- to 35-year-old and 65- to
85-year-old individuals stimulated with immobilized anti-CD3/
CD28 antibodies (Abs). ENTPD1 expression was low in unstimu-
lated cells and was induced by stimulation. Induction on day 3
after stimulation was 2-fold higher in the older population (Fig-
ure 1A). CD39 is inducible in central and effector memory CD4+
T cells, while end-differentiated TEMRA cells show lesser
expression (Figure 1B). CD39 expression on activated naive
CD4+ T cells is infrequent on day 4 (Figure 1B) but increases
on subsequent days (data not shown). The age-associated dif-
ference in ENTPD1 expression was due to a higher frequency
of CD39-expressing cells, which was seen for all T cell subsets.
Figure 1C summarizes cytometric results of CD4+ memory
T cells from 21 young and 23 older individuals stimulated with
myeloid DCs from a young adult and SEB/TSST-1. A phenotypic
characterization of CD39+ CD4+ T cells did not show any age-
associated differences (Figure 1D). CD39+ T cells displayed a
more activated phenotype with higher expression of CD25,
HLA-DR, OX40, PD-1, and CTLA-4 compared to the CD39-
T cell population. Expression of the IL-7 receptor was decreased
(Figure 1E). KLRG1 was equally infrequent in CD39+ and CD39
T cells (Figure 1F).
Functional Characterization of CD4+ T Cells Expressing
CD39 after Activation
CD39 is expressed on T regulatory (Treg) CD4+ T cells, where it
contributes to their regulatory activity by cleaving ATP and ADP
and generating AMP that is further converted by CD73 to the
immunosuppressive adenosine (Deaglio et al., 2007). In inflam-
matory lesions, Moncrieffe and colleagues distinguished two
types of cells, CD39+memory cells and CD39+ Tregs (MoncrieffeCell Ret al., 2010). We explored whether CD39+ CD4+ T cells gener-
ated in an immune response have Treg function. FOXP3 expres-
sion was not elevated in CD39+ activated T cells (Figure 2A).
Moreover, expression of CD39 andCD73wasmutually exclusive
(Figure 2B). In contrast to resting CD39+ Tregs that expressed
low levels of CD26 (Figure 2D) (Dong et al., 1997; Mandapathil
et al., 2010; Salgado et al., 2012), CD4+ T cells expressing
CD39 after activation have increased CD26 expression (Fig-
ure 2C), suggesting that even if adenosine is generated, it is
broken down to inosine. In functional assays, we could not
demonstrate immunosuppressive activity. CD39+ T cells were
generated by anti-CD3/CD28 stimulation of CD4+ T cells ob-
tained from individuals differing in their CD39SNP genotype (Fig-
ures 2E–2G). As expected, CD39 expression was infrequent in
T cells with an A/A SNP and high in T cells carrying the A/G or
G/G genotype. No positive correlation between the expression
of CD39 and suppressive activity on proliferative responses
was seen when the activated T cells were cocultured with fresh
naive carboxyfluorescein succinimidyl ester (CSFE)-labeled
CD4+ T cells activated with anti-CD3 Ab (Figure 2E). Moreover,
inhibition of the ATPase activity by the ATP antagonist ARL in
these coculture experiments did not increase the proliferative
response. We also could not detect significant inhibitory activity
on the polarization of naive T cells into Th1 or Th17 cells (Fig-
ure 2F) or interferon-g (IFN-g) production by effector T cells
(Figure 2G).
Since CD39 on activated CD4+ T cells did not confer regula-
tory function, we characterized the effector functions of these
cells. Compared to CD39- cells, expression of T-bet in CD39+
cells was higher, indicating that they have features of Th1
effector cells (Figure 3A). Cytokine profiling was performed af-
ter ionomycin/phorbol myristate acetate (PMA) restimulation on
day 4. To control for possible differences in activation status,
cells were gated for CD25 expression. Irrespective of age,
CD39+ CD4+ T cells were prone to produce IFN-g, IL-4, and
IL-17, while IL-2 and IL-21 production was decreased. Repre-
sentative scatterplots are shown in Figure 3B, and summary
data are shown in Figure 3C. While neither CD39+ nor CD39
cells expressed high levels of BCL6 under nonpolarizing culture
conditions, polarization with transforming growth factor-b
(TGF-b) and IL-23 induced BCL6 only in CD39 T cells (Fig-
ure 3D). Only CD39- CD4+ T cells were able to help B cell dif-
ferentiation into plasmablasts in vitro. In these assays, CD4+
T cells were stimulated with immobilized anti-CD3/CD28 Abs
for 4 days to induce CD39 expression and then separated
into CD39+ and CD39 cells, each of which was cocultured
with purified B cells from the same donor on immobilized
anti-CD3/CD28 Abs. After 6 more days of culture, plasmablasts
in the CD3 population were identified by staining for immuno-
globulin D (IgD) and CD38 (Figure 3E). Results are summarized
in Figure 3F. CD39+ cells were deficient in promoting B cell dif-
ferentiation, while CD39 activated T cells were as efficient as
total CD4+ T cells.
CD39+ T Cells Are Metabolically Stressed
Activation of the metabolic master regulator AMPK and shifts in
metabolic pathways are known to be important in CD8+ effector
T cells and their differentiation into long-lived memory cells (Rolfeports 14, 1218–1231, February 9, 2016 ª2016 The Authors 1219
Figure 1. CD4+ T Cells from Older Individuals Are Poised to Express the Ecto-ATPase CD39 upon Activation
(A) CD39 transcripts were quantified by qPCR in CD4+ memory T cells before and after 3-day stimulation with immobilized anti-CD3/CD28 Abs (n = 17). The
results are expressed as mean ± SEM of transcript numbers after normalization to 18sRNA.
(B) Subsets of CD4+ T cells were stimulated for 4 days, and CD39 expression was determined by cytometry. The example shown is representative of five young
and five older adults. CD39 expression in naive T cells further increased on day 6 after stimulation.
(C) CD4+memory T cells from twenty-one 20- to 35-year-old and twenty-three 65- to 85-year-old adults were stimulated with DCs and SEB/TSST-1 and analyzed
for the expression of CD39 on CD25+ CD4+ T cells by flow cytometry on day 4. Results are given as mean ± SEM.
(D) On day 5 after CD3/CD28 stimulation, expression of indicated activationmarkerswere analyzed by flow cytometry on gated CD39+ (red line) andCD39 T cells
(blue line). Shaded area represents isotype control. Histograms of T cells from a young and an elderly individual are representative of two experiments.
(E) Expression of CD127 (IL-7R) on gated CD39+ and CD39 T cells was assessed by flow cytometry. Results are shown as a representative histogram (left) and
mean ± SEM fluorescence intensity (MFI) of four experiments.
(F) Scatterplot of KLRG1 expression is representative of three experiments.
See also Table S1.et al., 2013). We quantified Thr172AMPK phosphorylation in
CD39+ and CD39 T cells in cultures two to five days after acti-
vation with immobilized anti-CD3/CD28 Abs. CD39+ T cells dis-
played significantly increased Thr172 phosphorylation of AMPK
(Figure 4A). Flow cytometric data were confirmed by western1220 Cell Reports 14, 1218–1231, February 9, 2016 ª2016 The Authoblotting of CD39+ and CD39 T cell subsets purified on day 4 af-
ter stimulation (Figure 4A, right). Consistent with the increased
AMPK phosphorylation, cytoplasmic ATP levels in CD39+
T cells were markedly reduced (Figure 4B). To exclude that
ongoing CD39 ATPase activity after cell lysis artificially loweredrs
Figure 2. CD39 Expressed on Activated CD4+ T Cells Does Not Confer Regulatory Activity
(A) CD39+ and CD39 CD4+ T cell subsets were separated after 5 days of stimulation with anti-CD3/CD28 Dynabeads. FOXP3 transcripts were quantified by
qPCR and are shown as mean ± SEM of seven experiments relative to 18 s rRNA transcripts.
(B and C) Anti-CD3/CD28-activated CD4+ T cells were assayed for the expression of CD73 (B) and CD26 (C) on CD39+ and CD39 cells by flow cytometry.
(D) CD26 expression on resting CD4+ Treg cells is shown for comparison.
(E–G) CD4+ T cells from individuals with the different CD39 SNP genotypes representing low, intermediate, and high CD39 expressers were stimulated by CD3/
CD28 cross-linking. Histograms in the upper row show the degree of CD39 expression depending on the SNP genotype. On day 4, activated CD4+ T cells were
added to fresh CD4+ T cells and immobilized anti-CD3/CD28 Abs. Regulatory activity on proliferation was assessed by CSFE dilution in the absence or presence
of 200 mMof the ATPase inhibitor ARL (E). Alternatively, activated T cells were assessed for their ability to inhibit polarization into Th1 or Th17 cells (F) or suppress
cytokine production of effector cells (G). Each dataset is representative of two experiments.
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ATP measurements, cytoplasm and membrane fractions from
CD39+ and CD39 T cells were isolated and ATP concentrations
were determined in mixtures of the different fractions. No evi-
dence of ongoing ATPase activity in any of these lysates was
found consistent with the enzyme activity strictly dependent on
C- and N-terminal membrane insertion.
ATP production in activated memory cells comes from the
glycolytic pathway with variable contribution from oxidative
phosphorylation. Expression of the rate-limiting glucose trans-
porter GLUT1 was slightly higher in CD39+ CD4+ T cells,
excluding that the increased metabolic stress was due to lower
glucose influx (Figure 4C). In contrast, mitochondrial function
was compromised in CD39+ T cells. Staining with the JC-1 dye
showed reduced aggregation in mitochondria of CD39+ T cells
(Figure 4D).
AMPK has a multitude of molecular targets that aim at main-
taining the energy balance of a cell. We have recently described
an increased expression of DUSP4 and EGR1, the transcription
factor that controls DUSP4 expression, as consequences of
increased AMPK phosphorylation in older CD4+ T cells. As
shown in Figure 4E, CD39+ CD4+ T cells exhibited increased
transcription of EGR1 and DUSP4. Nuclear DUSP4 expression
inhibits T cells’ ability to help B cell differentiation and to prolifer-
ate and induces cellular senescence (Tresini et al., 2007; Yu
et al., 2012). One other target of pAMPK is p53 that, when phos-
phorylated at Ser15, regulates p21 expression (Jones et al.,
2005). Phosphorylation of p53 at Ser15 was increased in
CD39+ CD4 T cells at days 4 and 5 after stimulation (Figure 4F).
In parallel, p21 expression at both mRNA and protein levels was
upregulated (Figure 4G). Upregulation of TIGAR transcripts,
another well-established target of Ser15 phosphorylated p53
(Bensaad et al., 2006), provided further evidence for the activa-
tion of this pathway (Figure 4H). Pharmacological inhibition of
AMPK activity reduced p53 phosphorylation and p21 in CD39+
cells (Figure 4I) and protected them from undergoing apoptosis
(Figure 4J; p = 0.0003). Based on the increased expression of
p21, CD39 T cells should have a competitive advantage over
CD39+ cells. We purified CD39+ and CD39 T cells on day 5 after
stimulation and labeled themwith CFSE and Claret, respectively.
The two cell types were then recombined and restimulated with
DCs and SEB/TSST-1 in the absence or presence of IL-2 and
IL-7. Cells deriving from CD39 T cells were enriched in the
cultures, even more so when proliferation was augmented by
the addition of IL-2 and IL-7, consistent with partial cell-cycle ar-
rest or increased apoptosis in CD39+ T cells that could not be
overcome by the cytokines (Figure 4K).
CD39+ T Cells Have Increased Susceptibility to Undergo
Apoptosis
After T cell activation and clonal expansion, most effector T cells
do not survive; only a few cells escape clonal contraction and
transit into long-lived memory cells. To determine whether
CD39 identifies cells that are prone to undergo apoptosis,
CD4+ T cell cultures were stained with Annexin V on day 4 after
activation. Close to 40% of CD39+ T cells in the cultures were
apoptotic compared to less than 10% of CD39 T cells (Fig-
ure 5A; p = 0.006). Decreased survival of CD39+ T cells was
also demonstrated when CD39 T cells were stained with1222 Cell Reports 14, 1218–1231, February 9, 2016 ª2016 The AuthoCSFE and cocultured with CD39+ cells without further restimula-
tion or addition of cytokines. Progenies of CD39 T cells slowly
accumulated in the cultures over the next 5 days from a 1:1 to
a 1.5:1 ratio (Figure 5B). Since cells only negligibly proliferated
under these conditions, results are consistent with reduced sur-
vival of CD39+ T cells.
BCL2 expression as determined by flow cytometry and by
qPCR was not different in the CD39+ and CD39 T cell subsets
(Figure 5C). Moreover, we did not see a difference in BIM, which
has been implicated in contraction of effector T cells (van Leeu-
wen et al., 2009; Williams et al., 2008) (Figure 5D). Since we
found evidence for Ser15-phosphorylated p53 in CD39+ T cells
(Figure 4F), we analyzed the expression of pro-apoptotic genes
that are controlled by p53. We did not find increased expression
of PUMA (Figure 5E). However, expression of BAX was
increased at the transcript as well as the protein level (Figure 5F).
Moreover, we found evidence of BAX activation in CD39+ T cells
as evidenced by the presence of BAX oligomers in CD39+, but
not CD39 T cells (Figure 5G).
ATPase Activity of ENTPD1 Contributes to the
Functional Profile of CD39+ T Cells
We have shown so far that CD39 is a phenotypic marker of
effector cells that are metabolically stressed and more prone
to undergo apoptosis. ATPase activity of ENTPD1 is strictly
extracellular, but it can modify signals from ATP and its deriva-
tives through purinergic receptors. To determine whether the
ATPase activity contributes to the characteristic profiles of
CD39+ cells, we activated CD4+ T cells and cultured them in
the presence or absence of an ATPase inhibitor, ARL. Cells
were restimulated on day 4 with ionomycin and PMA and as-
sayed for the production of cytokines. ARL increased the pro-
duction of IL-2 and IL-21 while reducing IFN-g production in
CD39+ cells (Figures 6A and 6B). In contrast, ARL only had a
slight and nonsignificant effect on the frequencies of cyto-
kine-producing cells in CD39 cells, presumably indirectly by
blocking CD39 on CD39-positive cells present in the same cul-
tures. Moreover, ENTPD1 transfection of CD4+ T cells from an
A/A donor and subsequent activation selected for IFN-g and
against IL-2-producing cells (Figure 6C). ARL also partially
restored the ability of CD39+ T cells to provide help for B cell
differentiation (Figure 6D). These data support the notion that
the ATPase activity of CD39 reinforces effector cell
differentiation.
ATPase Activity of ENTPD1 Contributes to Apoptosis
and Attrition of Expanded Effector Cells
Frequencies of apoptotic cells decreased when cultures
were performed in the presence of the ENTPD1 inhibitors ARL
(Figure 7A; p = 0.0004) and POM-1 (Figure 7B; p < 0.0001), sug-
gesting that the ATPase activity contributes to the apoptotic sus-
ceptibility of CD39+ T cells. A2A receptor blocking showed that
at least in part the induction of apoptosis wasmediated by aden-
osine (Figure 7C; p = 0.0002). In addition to proximity of adeno-
sine generation, increased A2AR expression on CD39+ cells may
contribute to their higher sensitivity to undergo apoptosis (Fig-
ure 7D). Moreover, inhibition of CD39 activity also reduced
pAMPK in CD39+ cells (Figure 7E; p = 0.03), while addition ofrs
(legend on next page)
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adenosine to CD39 T cells induced AMPK phosphorylation
(Figure 7F). To provide further evidence, CD4+ T cells were trans-
fected with a construct encoding GFP and CD39 and examined
for the frequencies of apoptotic cells 48 hr after transfection.
GFP+ cells transfected with the control plasmid had frequencies
of 20% Annexin V+ cells, most of which lacked staining for
7-AAD. In contrast, 50% of CD39+ GFP+ cells were Annexin
V+, half of which costained with 7-AAD (Figure 7G).
Since ENTPD1 ATPase activity contributed to the apoptotic
susceptibility, we reasoned that individuals lacking CD39
expressionmay have lesser T cell contraction in a T cell response
and therefore benefit more from vaccination. Frequencies of
IFN-g–producing virus-specific T cells were quantified before
and four weeks after vaccination by ELISpot in 28 healthy indi-
viduals older than 50 years who had received immunization
with the live varicella zoster virus (VZV) vaccine Zostavax. Cyto-
metric analysis of VZV-specific CD4+ T cells with an HLA-
DRB1*1501 tetramer including the VZV IE63-derived peptide
QRAIERYAGAETAEY after vaccination showed CD39 expres-
sion on a subset of cells (Figure 7H). Individuals with the A
SNP that is associated with lower CD39 expression tended to
have a higher fold increase in VZV-specific T cells than individ-
uals carrying a G genotype (p = 0.1 by trend test; Figure 7I).
Similar results were obtained in an influenza vaccination cohort
of 74 adults older than 60 years, 42 of whom had serological
evidence of prior cytomegalovirus (CMV) infection. After adjust-
ing for CMV status, a significant influence of the CD39 SNP ge-
notype was seen for the frequencies of virus-specific T cells after
vaccination with the A/Victoria (AA versus AG, p = 0.019; AA
versus GG, p = 0.016) and B/Wisconsin strains (AA versus GG,
p = 0.004, trend test for the association of A with fold increase
in antigen-specific T cell frequencies, p = 0.008; Figure 7J). No
difference was seen for the vaccination with the California strain.
Cumulatively, these data suggest that theENTPD1G genotype is
associated with a lesser gain in long-lived memory T cells after
vaccination. These data document a negative function of CD39
on T memory formation in vivo that, although not excluding
CD39-mediated Treg activity, is consistent with the proposed
model of increased clonal contraction of CD39-expressing
effector T cells.
In addition to vaccine responses, the CD39 SNP status also
has an impact on the T cell memory to chronic viral responses.
A subset of CMV carriers has an expanded subset of end-differ-
entiated effector cells known as TEMRA that are considered to
reflect chronic stimulation due to viral reactivation. CD4+ TEMRA
T cells are lower in CMV-positive individuals with the A versus the
G genotype (Figure 7K), while no association was seen in CMV-
negative individuals (p = 0.8).Figure 3. Functional Characterization of CD4+ T cells Expressing CD39
(A) T-bet transcripts were quantified as described in Figure 2A for FOXP3.
(B and C) CD4+ T cells, stimulated with anti-CD3/CD28 Dynabeads for 4 days, we
2 hr. Contour plots of intracellular cytokine expression in gated CD25+CD39+ and
of six to seven experiments (C) are shown.
(D) CD39+ and CD39 cells were generated under nonpolarizing and TFH-polariz
(E and F) CD39+ andCD39 cells were isolated from activated CD4+ T cells, mitom
CD28 Abs for 6 additional days. Contour plots of CD38 and IgD expression on C
experiments are shown as mean ± SEM (F).
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After a period of rapid expansion upon antigen stimulation, most
of the responding T cells die from apoptosis and do not transition
into long-livedmemory cells. The factors that determine differen-
tiation and survival are of central importance for successful
memory formation after infection and vaccination. While prog-
ress has been made in mouse models to identify memory cell
precursors, the process remains poorly defined in humans.
Here, we describe that the expression of CD39 on activated
CD4+ T cells identifies effector cells that are prone to culling
due to activation of the AMPK-p53 pathway. CD39 transfection
experiments identified a direct role of CD39 in influencing
effector cell differentiation and T cell attrition. Pharmacological
inhibition experiments employing several distinct inhibitors sup-
port the notion that its ATP/ADPase activity is involved in these
effects. Since CD39 is more readily induced in older individuals,
increased attrition of effector T cells may contribute to the
impaired vaccine responses with age.
CD39 is an ecto-ATPase that cleaves ATP to ADP and AMP.
By cleaving ATP, CD39 influences purinergic signals through
ionotropic P2X and G-protein-coupled P2Y receptors (Boey-
naems et al., 2005). AMP generated by CD39 can be further
cleaved byCD73. The concerted activity of CD39 andCD73 gen-
erates adenosine, which is considered an important pathway for
Tregs to exert their immunosuppressive function (Deaglio et al.,
2007; Ohta and Sitkovsky, 2014). Although we found evidence of
adenosine production, we did not find regulatory activities in
T cells gaining CD39 expression after activation, possibly due
to increased expression of CD26 that binds adenosine deami-
nase in humans, thereby facilitating the deamination to inosine
(Dong et al., 1997; Mandapathil et al., 2010; Salgado et al.,
2012). Several investigators have shown considerable heteroge-
neity within the CD39+ T cell subset. Although a transcriptional
signature of FOXP3+ Tregs includes ENTPD1 transcripts,
expression levels do not correlate with suppressive activity
(Ferraro et al., 2014). CD39+ CD4+ memory T cells that do not
express FOXP3 and lack Treg function but produce effector cy-
tokines have been described in the setting of kidney transplanta-
tion and chronic synovitis in vivo (Dwyer et al., 2010; Moncrieffe
et al., 2010). The profile of these ex vivo cells is similar to the cells
described here.
The reasons why CD39 is only induced in a subset of T cells
and why these cells are enriched with age are unknown. Func-
tionally, CD39+ differ from CD39- CD4+ T cell in that they are
highly differentiated effector T cells with increased expression
of T-bet, higher production of effector cytokines and lower
production of IL-2. Since IL-4, IL-17 and IFN-g are equallyafter Activation
re restimulated with 2.5 ng/ml PMA and 500 ng/ml ionomycin for an additional
CD25+CD39 cells from a 27- and a 65-year-old individual (B) andmean ± SEM
ing conditions (n = 4) and compared for the expression of BCL6.
ycin treated, and cocultured with autologous B cells and immobilized anti-CD3/
D3 cells are shown (E). Frequencies of IgDCD38high plasmablasts from four
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Figure 4. Activated CD4+ T Cells Expressing CD39 Are Metabolically Stressed
(A) CD4+ T cells were analyzed for AMPK phosphorylation on days 2–5 after anti-CD3/CD28 Abs stimulation. Results from flow cytometry of six experiments are
shown for gated CD25+ CD39+ and CD25+ CD39 T cells as mean ± SEM geometric mean fluorescence intensity normalized to forward scatter (left). Western
blots of isolated T cell subsets from a young and an older adult on day 4 after stimulation (right) are representative of two independent experiments.
(B) Intracellular ATP concentrations in lysates of purified CD39+ and CD39 cells from activated CD4+ T cells were determined using a luciferase kit (n = 8).
(C) GLUT1 mRNA expression was quantified by qPCR in CD39+ and CD39 activated T cells from seven individuals.
(D) Mitochondrial membrane potentials in day 5 activated CD4+ T cells were assessed. Results are given as the mean ± SEM JC-1 aggregate: monomer
ratio (n = 8).
(E) CD39+ and CD39 cells isolated from activated CD4+ T cells were analyzed for DUSP4 and EGR1 expression by qPCR (n = 7).
(F) Ser15-phosphorylated p53 in CD39+ and CD39 cells was determined by western blot. Results for four adults, S1–S4, are representative of six individuals.
(G) p21 transcripts were quantified by qPCR (n = 7, left). Expression of p21 proteins in CD39 and CD39+ T cells were compared by flow cytometry on days 2–5
(n = 4, middle) and by western blot on day 4 (n = 7, right).
(H) TIGAR mRNA expression was quantified by qPCR (n = 7).
(I and J) CD4+ T cells were activated in the presence of the AMPK inhibitor Compound C. Western blots show the expression of pAMPK, p-p53, and p21 (I). The
effect of pAMPK inhibition on apoptosis rates is shown in (J).
(K) CD39+ and CD39 cells were purified from activated CD4+ T cells and stained with CFSE and Claret, respectively. Cells were mixed at a 1:1 ratio and
restimulated with DCs and SEB/TSST-1 with or without IL-2 and IL-7 for another 6 days. Results are representative of two experiments.
*p < 0.05, **p% 0.01, ***p% 0.001
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Figure 5. Activated CD4+ T Cells Expressing CD39 Are Susceptible to Undergo Apoptosis
(A) Activated CD4+ T cells from eight individuals were assessed for the frequencies of apoptotic cells on day 4 after anti-CD3/CD28 stimulation. The percentages
of Annexin V+ apoptotic cells within the populations of CD25+ CD39+ and CD25+ CD39 T cells are shown as mean ± SEM.
(B) CD39- T cells were purified from activated CD4+ T cells, stained with CFSE, and recombined with CD39+ T cells at a 1:1 ratio. Relative survival of the two
subsets was monitored over the next 5 days by flow cytometry.
(C) BCL2 expression in CD25+ CD39+ and CD25+ CD39 T cells was determined by flow cytometry on days 2–5 after anti-CD3/CD28 stimulation. Results are
shown as mean ± SEM geometric MFI normalized to forward scatter (n = 6). BCL2 transcripts were quantified in purified CD39+ and CD39 T cells by qPCR
(right, n = 6).
(D and E) Expression of BIM (D) and PUMA (E) was determined by western blot.
(F) BAX transcripts were quantified by qPCR (left panel, mean ± SEM, n = 13). BAX protein was detected by flow cytometry (middle) (mean ± SEM geometric MFI
normalized to forward scatter, n = 7, **p% 0.01, ***p% 0.001) and western blotting (right).
(G) BAX oligomerization in CD39+ and CD39 T cells purified from activated CD4+ T cells from a young, middle-aged, and older adult was assessed by western
blotting under nonreducing condition. One experiment representative of three is shown.
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Figure 6. ATPase Activity of ENTPD1 Contributes to the Functional Profile of Activated CD4+ T Cells Expressing CD39
(A and B) CD4+ T cells were activated by CD3/CD28 stimulation, ARL (0, 400 mM) was added on day 1, and cytokine expression was determined after PMA/
ionomycin restimulation on day 4. Results are shown as representative contour plots (A) and mean ± SEM of four or five experiments (B).
(C) Overnight-stimulated CD4+ T cells from an individual with the CD39 A/A SNP were transfected with a CD39-pEGFP-C1 or a pEGFP-C1 control construct and
stimulated with anti-CD3/CD28 Abs. Cytokine production after ionomycin/PMA restimulation on day 5 after stimulation is shown as contour plots; data are
representative of two experiments.
(D) CD4+ T cells were activated and ARL (0, 200 mM) was added on day 1 of stimulation. The ability of CD39+ and CD39 T cells to provide help for B cells to
differentiate into plasmablast was assessed as described in Figure 3E and determined by flow cytometry. Data are representative of two experiments.increased, CD39 expression is not lineage specific except that
CD39+ T cells produce less IL-21 and are unable to provide
help for B cell differentiation.
Importantly, expression of CD39 appears not only to be a sub-
set-specific marker, but its ATPase activity appears to be
directly involved in effector cell differentiation. ATPase inhibition
during T cell differentiation improved the ability to produce IL-2
and IL-21 and restored the ability to help B cells. CD39 silencing
experiments were inconclusive due to the high apoptosis sus-
ceptibility of these effector cells, but we used two chemically
different ATPase inhibitors and off-target effects are thereforeCell Runlikely to account for the effects. Moreover, we observed a
clear difference of ARL inhibition on CD39+ and CD39 T cells.
CD39 may exert its effect on T cell differentiation by preventing
a signal by ATP through a P2X receptor. P2X7 is widely ex-
pressed on T cells and requires high ATP concentrations to
induce a Ca2+ influx. P2X7-mediated autocrine activity of ATP
during TCR stimulation has been shown to mediate a costimula-
tory signal (Schenk et al., 2008; Yip et al., 2009). Activated T cells
also transcribe many P2Y receptors; P2Y1, P2Y12, and P2Y13
preferentially sense ADP and could transmit a signal in response
to the CD39-generated ADP. Finally, AMP generated by CD39 iseports 14, 1218–1231, February 9, 2016 ª2016 The Authors 1227
further cleaved to adenosine, likely by CD73-containing exo-
somes in the culture (Clayton et al., 2011).
CD39+ CD4+ effector T cells are highly susceptible to undergo
apoptosis, suggesting that CD39 identifies effector cells that are
subject to contraction and do not develop into long-lived mem-
ory cells. Given the central role of T cell memory formation in
adaptive immunity, defining the mechanisms how T cells survive
the contraction phase and develop into memory cells has been
of keen interest. Elegant studies in murine infectious disease
models identified KLRG1 in CD8+ T cells as a phenotypic marker
distinguishing apoptosis-prone effector T cells from cells that
differentiate into memory cells (Sarkar et al., 2008). KLRG1 is ab-
sent on most CD4+ T cells, including CD39+ cells (Figure 1F).
Marshall and colleagues proposed high expression of Ly6C as
marking CD4+ effector T cells that do not survive (Marshall
et al., 2011). A human gene corresponding to Ly6C does not
exist. However, murine KLRG1high CD8+, murine Ly6Chigh
CD4+, and human CD39+ CD4+ T cells are similar in that they
are highly differentiated effector cells with high expression of
T-bet. In mouse CD8+ T cells, T-bet has a direct influence on
survival by repressing transcription of the IL-7 receptor (In-
tlekofer et al., 2007). Similarly, CD39+ CD4+ T cells lacked IL-7
receptor expression (Figure 1E). In murine studies, central mem-
ory cell differentiation is supported by BCL6 and ICOS-mediated
interaction with B cells (Pepper et al., 2011). Analogously, human
CD39+ T cells are not able to provide help for B cell differentiation
(Figures 3E and 3F).
In contrast to clonal contraction in the mouse (van Leeuwen
et al., 2009; Williams et al., 2008), the increased apoptosis sus-
ceptibility of CD39+ T cells was not related to an imbalance be-
tween BCL2 and BIM. CD39+ T cells activate the p53 pathway
to enter senescence or to undergo apoptosis (Figures 4 and 5).
Downstream of p53, p21 transcription is induced, causing cell-
cycle arrest. In parallel, expression and activation of BAX is
increased, both controlled by p53 (Chipuk et al., 2004; Miyashita
and Reed, 1995). In contrast, expression of PUMA, also regu-
lated by p53, was not different between CD39 and CD39+
T cells.
Apoptosis susceptibility was directly related to the expression
of CD39. Transfecting CD39 T cells with CD39 conferred
increased cell death (Figure 7G). Conversely, inhibition of its
ATPase activity improved survival of CD39+ T cells (Figures 7A
and 7B). We could partially block apoptosis by inhibiting the
stimulation of the A2A receptor by adenosine (Figure 7C), pre-
sumably generated from further degradation of AMP by exo-
somes that are produced by CD73-expressing cells present in
the culture system (Clayton et al., 2011). The high expression
of the A2AR receptor on CD39+ T cells may favor suicide over
fratricide (Figure 7D). Possibly more importantly, extracellular
adenosine, taken up by adenosine transporters, has been shown
to induce AMPK activation (Aymerich et al., 2006; Nieminen
et al., 2013). Indeed, we found that adenosine induces AMPK
phosphorylation in CD39 T cells (Figure 7F). In addition to acti-
vating p53, AMPK regulates transcription of stress-inducible
genes by directly promoting histone H2B phosphorylation (Bun-
gard et al., 2010). These direct transcriptional activities of AMPK
do not include PUMA, which may explain why PUMA was not
different between CD39 and CD39+ T cells.1228 Cell Reports 14, 1218–1231, February 9, 2016 ª2016 The AuthoGeneration of extracellular adenosine may not be the only
mechanism that accounted for the increased AMPK phosphory-
lation. Increased anabolic activity associated with T cell prolifer-
ation causes metabolic stress and activates AMPK. We found
expression of GLUT1 is even higher in CD39+ T cells than in
CD39 T cells, indicating that the glycolytic pathway is intact.
However, CD39+ T cells had low cytoplasmic concentrations of
ATP. Since mitochondrial function was impaired in CD39+
T cells, they may be unable to produce sufficient ATP by oxida-
tive phosphorylation and therefore initiate the apoptotic path-
ways. CD39 may be directly involved, since a similarly reduced
cytoplasmic concentration of ATP has also been recently
described for CD39+ Tregs (Zhao et al., 2010).
In contrast to our model for human CD4+ effector T cells,
where pAMPK induces cell-cycle arrest and apoptosis, activa-
tion of AMPK or inhibition of mTORC1 has been shown to sup-
port the effector to memory cell transition stage for murine
CD8+ T cells (Araki et al., 2009; Rolf et al., 2013). Differences
in the requirements of CD4+ and CD8+ T cells for mTORC1
activity are supported by the finding that mTORC1 inhibition in-
duces anergy or Tregs and does not improve memory in CD4+
T cells (Powell and Delgoffe, 2010; Xie et al., 2012). Moreover,
extent and context of AMPK activation that determine whether
the outcome is apoptosis, cell-cycle inhibition, or survival may
be different.
Our in vitro studies provide evidence for the model that CD39
is not only a biomarker but also that its ATPase activity is mech-
anistically involved in effector cell differentiation and controls the
clonal contraction seen in the transition from effector to long-
livedmemory cells. This interpretation is supported by our in vivo
findings that individuals defective in CD39 expression had a
higher increase in antigen-specific memory T cells after vaccina-
tion with VZV and two out of the three influenza strains. In this
model, the increased expression of CD39 seen with CD4+
T cells from older individuals could contribute to their reduced
ability to respond to vaccination. CD39 inhibitors, currently under
development in oncology, could be explored to improvememory
cell generation. Also, A2A receptor antagonists may be effective,
since at least part of the CD39 effect is mediated by A2A stimu-
lation by adenosine.
EXPERIMENTAL PROCEDURES
Detailed description of the methods used for cell isolation and culture, flow
cytometry, ELISpot, qPCR, immunoblotting, and statistical analysis can be
found in Supplemental Experimental Procedures.
Study Population
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy indi-
viduals 20–85 years of age. 28 individuals older than 50 years were vaccinated
with the VZV vaccine Zostavax. 74 individuals older than 60 years and with
known CMV serology were enrolled in a vaccine study with the trivalent influ-
enza vaccine Fluzone in the 2012/2013 season. Individuals were genotyped for
the CD39 rs_10748643 SNP by PCR with 0.25 ml specific forward/reverse
primers and probes (allele 1: VIC/MGB-NFQ; allele 2: FAM/MGB-NFQ; Applied
Biosystems) in quintuplicates in 384-well plates using the ABI 7900HT system.
The study was approved by the Stanford institutional review board, and partic-
ipants gave informed consent. CD39+ T cells were generated by in vitro
stimulation of CD4 subsets as described in Supplemental Experimental
Procedures.rs
Figure 7. ATPase Activity of ENTPD1 Contributes to the Susceptibility of Activated CD4+ T Cells to Undergo Apoptosis and Clonal
Contraction
(A and B) CD4+ T cells were activated by anti-CD3/CD28 Abs; the ATPase inhibitors ARL (A) or POM-1 (B) were added on day 1 for 3 days or day 4 for 6 hr, and
percentages of apoptotic cells were determined by staining for Annexin V on day 4.
(C) Binding of adenosine to the A2A receptor was blocked by adding 10 mM SCH on day 1 after activation. Apoptotic rate was determined on day 4.
(D) Anti-CD3/CD28 activated CD4+ T cells were assessed for the expression of the adenosine receptor A2AR. Flow cytometric results (mean ± SEM from seven
individuals, top) and western blots from four individuals (bottom) are shown.
(E and F) Phosphorylation of AMPK was assessed for CD39+ T cells cultured with the ATPase inhibitor ARL (E) and in CD39 T cells cultured with increasing
concentrations of adenosine (F).
(G) CD4+ T cells from an individual with the CD39 A/A SNP were transfected with a CD39-pEGFP-C1 or a pEGFP-C1 control construct. 48 hr after transfection,
apoptotic cells in gated pEGFP+ cells were determined by staining with 7-AAD and Annexin V. Scatterplots are representative of two experiments.
(H–J) Healthy individuals were vaccinated with the varicella zoster virus (VZV) vaccine Zostavax. A subset of CD4+ T cells specific for a VZV IE63 peptide in the
context of HLA-DRB1*1501, as defined by major histocompatibility complex class II tetramer staining, expressed CD39 after vaccination (H). Vaccinated
(legend continued on next page)
Cell Reports 14, 1218–1231, February 9, 2016 ª2016 The Authors 1229
Pharmacological Assays
To inhibit CD39 ATPase activity, 100–400 mM of the nondiffusible ATPase in-
hibitor ARL 67156 trisodium salt (Tocris) was added to cultures on day 1 after
anti-CD3/CD28 Abs activation. Functional assays (cytokine production, T/B
cell coculture), apoptosis assays, and flow cytometry for pAMPK on CD39+
T cells were performed on day 4. Alternatively, ATPase activity was inhibited
in day 4 activated CD4+ T cells with 10 or 50 mM of the ENTPD inhibitor
POM-1 (TOCRIS) for 6 hr before assaying apoptosis.
To block adenosine stimulation of the A2A receptor, SCH 442416 (Tocris)
was added at a concentration of 10 mM on day 1 after initial stimulation.
To inhibit pAMPK activity, 2 mM Compound C (Sigma-Aldrich) or control
DMSO was added to CD4+ T cell cultures on day 1 after stimulation with
anti-CD3/CD28 beads. pAMPK, p-p53 (ser15), and p21 expression in CD39+
T cells was determined by western blotting; apoptosis was determined by
flow cytometry.
Adenosine (0.5, 1.0, or 1.5 mM; Sigma-Aldrich) was added to CD4+ T cell
cultures on day 3 after stimulation. Phosphorylation of AMPK in purified
treated and untreated CD39 CD4 T cells was examined by western blotting
on day 4.
CD39 Transfection
CD4+ T cells of the low-expressor A/A SNP genotype were transfected with
3 mg CD39-pEGFP-C1 or 3 mg pEGFP-C1 construct (as a negative control) us-
ing the Lonza 4D-Nucleofector system and Amaxa P3 Primary cell 4D-Nucle-
ofector kit (Lonza). 48 hr after transfection, cells were stainedwith APC-labeled
Annexin V and 7-AAD to assess apoptosis rates in GFP-expressing cells. Alter-
natively, CD4+ T cells were stimulated first with anti-CD3/28 overnight, then
transfected followed by additional 4 days of stimulation. Cells were then re-
stimulated with ionomycin/PMA and intracellular cytokines in GFP+ cells
were determined by cytometry.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two tables and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.01.002.
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